Literature DB >> 31328790

The novel cannabinoid CB1 receptor agonist AM11101 increases food intake in female rats.

Sean B Ogden1, Michael S Malamas2, Alexandros Makriyannis2, Lisa A Eckel1.   

Abstract

BACKGROUND AND
PURPOSE: Δ9 -tetrahydrocannabinol (THC) acts via cannabinoid CB1 receptors to increase feeding. Here, we assessed the orexigenic effect of AM11101, a novel CB1 receptor agonist designed to have a more favourable pharmacodynamic profile than THC. EXPERIMENTAL APPROACH: The acute, orexigenic effects of AM11101 and THC were compared in female rats. Food intake and meal patterns were also examined following once daily treatment with AM11101 and THC for 7 days. KEY
RESULTS: AM11101 (0.01-0.1 mg·kg-1 ) increased food intake during the first hour following both acute and chronic treatments in pre-fed and freely feeding animals. This orexigenic effect persisted for up to 4 hr, with no compensatory decrease in feeding during the subsequent 4-22 hr. THC (1 mg·kg-1 ) increased 1-hr food intake in pre-fed animals, but was less reliable than AM11101 in increasing 1-hr food intake in freely feeding animals following both acute and chronic administration. The orexigenic effect of both compounds was due to an increase in meal size, not meal number. CONCLUSIONS AND IMPLICATIONS: Our study provides the first demonstration that AM11101 increases short-term food intake via a selective increase in meal size. AM11101 promotes a more reliable orexigenic effect than THC in freely feeding animals, with no subsequent compensatory decrease in feeding. AM11101 may offer a greater efficacy than THC and its congeners in stimulating food intake in underweight clinical populations.
© 2019 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31328790      PMCID: PMC6811743          DOI: 10.1111/bph.14797

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  56 in total

1.  Animal research: reporting in vivo experiments: the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  An introduction to eating disorders: clinical presentation, epidemiology, and prognosis.

Authors:  Catherine A Miller; Neville H Golden
Journal:  Nutr Clin Pract       Date:  2010-04       Impact factor: 3.080

3.  Effect of delta9-tetrahydrocannabinol on quinine palatability and AM251 on sucrose and quinine palatability using the taste reactivity test.

Authors:  Maegan M Jarrett; Jordan Scantlebury; Linda A Parker
Journal:  Physiol Behav       Date:  2006-11-21

4.  Activity-based anorexia in C57/BL6 mice: effects of the phytocannabinoid, Delta9-tetrahydrocannabinol (THC) and the anandamide analogue, OMDM-2.

Authors:  David Y Lewis; Ros R Brett
Journal:  Eur Neuropsychopharmacol       Date:  2010-05-14       Impact factor: 4.600

5.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors.

Authors:  Stephen Ph Alexander; Arthur Christopoulos; Anthony P Davenport; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

6.  The major plant-derived cannabinoid Δ(9)-tetrahydrocannabinol promotes hypertrophy and macrophage infiltration in adipose tissue.

Authors:  A Wong; N Gunasekaran; D P Hancock; G S Denyer; L Meng; J L Radford; I S McGregor; J C Arnold
Journal:  Horm Metab Res       Date:  2011-12-21       Impact factor: 2.936

7.  The novel cannabinoid CB1 receptor agonist AM11101 increases food intake in female rats.

Authors:  Sean B Ogden; Michael S Malamas; Alexandros Makriyannis; Lisa A Eckel
Journal:  Br J Pharmacol       Date:  2019-09-06       Impact factor: 8.739

8.  Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency.

Authors:  B F Thomas; D R Compton; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

9.  Antagonism of ∆⁹-THC induced behavioral effects by rimonabant: time course studies in rats.

Authors:  Torbjörn U C Järbe; Roger S Gifford; Alexandros Makriyannis
Journal:  Eur J Pharmacol       Date:  2010-09-18       Impact factor: 4.432

Review 10.  Tetrahydrocannabinol and endocannabinoids in feeding and appetite.

Authors:  Elliot M Berry; Raphael Mechoulam
Journal:  Pharmacol Ther       Date:  2002-08       Impact factor: 12.310

View more
  4 in total

1.  The novel cannabinoid CB1 receptor agonist AM11101 increases food intake in female rats.

Authors:  Sean B Ogden; Michael S Malamas; Alexandros Makriyannis; Lisa A Eckel
Journal:  Br J Pharmacol       Date:  2019-09-06       Impact factor: 8.739

2.  In Vitro and In Silico Characterization of G-Protein Coupled Receptor (GPCR) Targets of Phlorofucofuroeckol-A and Dieckol.

Authors:  Pradeep Paudel; Su Hui Seong; Se Eun Park; Jong Hoon Ryu; Hyun Ah Jung; Jae Sue Choi
Journal:  Mar Drugs       Date:  2021-06-04       Impact factor: 5.118

Review 3.  A Guide to Targeting the Endocannabinoid System in Drug Design.

Authors:  Adam Stasiulewicz; Katarzyna Znajdek; Monika Grudzień; Tomasz Pawiński; And Joanna I Sulkowska
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 5.923

Review 4.  Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.

Authors:  Thomas Murphy; Bernard Le Foll
Journal:  Biomolecules       Date:  2020-06-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.